Rachel Brazil is a science writer based in London, UK
The early access to medicines scheme has been running for six years, but has it had the desired impact of ensuring the sickest patients are spared the wait for the most promising treatments, or is it failing to live up to expectations?
The under-representation of women in clinical trials is slowly being addressed, but we cannot move towards truly personalised healthcare unless we have an equal balance of the sexes in all new medicine trials.
Study results suggest that PDE-5 inhibitors could have a role in treating cancer, heart failure, neurodegenerative diseases, circulatory disorders and even infectious diseases, but the road to approval for new indications may not be smooth.
Stopping whooping cough in its tracksSubscription
Binning the sharps: the quest for oral insulinSubscription
Photopharmacology: using light to activate drugsSubscription